Insights into natriuretic peptides in heart failure: An update

Current Heart Failure Reports

Volumn 5, Issue 2, 2008, Pages 97-104

  Korinek, Josef ^a   Boerrigter, Guido ^a   Mohammed, Selma F ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; ALBUMIN; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR ALPHA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDOXATRIL; DENDROASPIS NATRIURETIC FACTOR; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE INHIBITOR; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; NITRIC ACID DERIVATIVE; OMAPATRILAT; PLACEBO; RECOMBINANT NATRIURETIC FACTOR; RECOMBINANT PROTEIN; SILDENAFIL; SNAKE VENOM NATRIURETIC FACTOR; TAIPAN NATRIURETIC FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; URODILATIN; VASODILATOR AGENT; VASONATRIN; VASOPEPTIDASE INHIBITOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP;

CHIMERA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERVOLEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIDE EFFECT; ACUTE DISEASE; CHRONIC DISEASE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; FEMALE; HEART FAILURE; HOSPITALIZATION; MALE; METABOLISM; MORTALITY; PHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ACUTE DISEASE; CHRONIC DISEASE; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NATRIURETIC PEPTIDES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 53949104793     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-008-0016-y     Document Type: Review

References (60)

1. Pankow K, Wang Y, Gembardt F, et al.: Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 2007, 101:875-882.
2. Brandt I, Lambeir AM, Ketelslegers JM, et al.: Dipeptidylpeptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006, 52:82-87.
3. Huntley BK, Sandberg SM, Noser JA, et al.: BNP-induced activation of cGMP in human cardiac fibroblasts: Interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol 2006, 209:943-949.
4. Stevens TL, Borgeson DD, Luchner A, et al.: A modified model of tachycardia-induced cardiomyopathy: Insights into humoral and renal adaptations. In Pathophysiology of Tachycardia-Induced Heart Failure. Edited by Spinale FG. New York: Futura Publishing; 1996:133-151.
5. Charloux A, Piquard F, Doutreleau S, et al.: Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 2003, 33:769-778.
6. Knecht M, Pagel I, Langenickel T, et al.: Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci 2002, 71:2701-2712.
7. Cataliotti A, Chen HH, Redfield MM, Burnett JC Jr: Natriuretic peptides as regulators of myocardial structure and function: Pathophysiologic and therapeutic implications. Heart Fail Clin 2006, 2:269-276.
8. Asano K, Dutcher DL, Port JD, et al.: Selective down-regulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 1997, 95:1193-1200.
9. Leader B, Baca QA, Golan DE: Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008, 7:21-39.
10. Cataliotti A, Schirger JA, Martin FL, et al.: Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation 2005, 112:836-840.
11. Yamamoto K, Burnett JC Jr, Redfield MM: Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 1997, 273:H2406-H2414.
12. Brunner-La Rocca HP, Kaye DM, Woods RL, et al.: Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001, 37:1221-1227.
13. Mitrovic V, Seferovic PM, Simeunovic D, et al.: Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006, 27:2823-2832.
14. Chen HH, Cataliotti A, Schirger JA, et al.: Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1093-R1097.
15. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487-1491.
16. Riter HG, Redfield MM, Burnett JC, Chen HH: Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 2006, 47:2334-2335.
17. Witteles RM, Kao D, Christopherson D, et al.: Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: A randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 2007, 50:1835-1840.
18. Kurien S, Warfield KT, Wood CM, Miller WL: Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide. Am J Cardiol 2006, 98:1627-1630.
19. Arora S, Clarke K, Srinivasan V, Gradman A: Effect of nesiritide on renal function in patients admitted for decompensated heart failure. QJM 2007, 100:699-706.
20. Wang DJ, Dowling TC, Meadows D, et al.: Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004, 110:1620-1625.
21. Cody RJ, Atlas SA, Laragh JH, et al.: Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986, 78:1362-1374.
22. Chen HH, Grantham JA, Schirger JA, et al.: Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 2000, 36:1706-1712.
23. Chen HH, Sundt TM, Cook DJ, et al.: Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: A double-blind placebo-controlled pilot study. Circulation 2007, 116:1134-1138.
24. Mentzer RM Jr, Oz MC, Sladen RN, et al.: Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: The NAPA trial. J Am Coll Cardiol 2007, 49:716-726.
25. Miller WL, Kurien S, Warfield KT, et al.: Lack of association between worsening renal function and mortality in heart failure patients treated with nesiritide. Int J Cardiol 2007 May 4 (Epub ahead of print).
26. Scriven TA, Burnett JC Jr: Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation 1985, 72:892-897.
27. Chen HH, Schirger JA, Chau WL, et al.: Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 1999, 100:2443-2448.
28. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K: Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005, 293:1900-1905.
29. Hauptman PJ, Schnitzler MA, Swindle J, Burroughs TE: Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA 2006, 296:1877-1884.
30. Arora RR, Venkatesh PK, Molnar J: Short and long-term mortality with nesiritide. Am Heart J 2006, 152:1084-1090.
31. Abraham WT, Adams KF, Fonarow GC, et al.: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005, 46:57-64.
32. Costanzo MR, Johannes RS, Pine M, et al.: The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: A propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J 2007, 154:267-277.
33. Patel JB, Valencik ML, Pritchett AM, et al.: Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 2005, 289:H777-H784.
34. Lainchbury JG, Burnett JC Jr, Meyer D, Redfield MM: Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol 2000, 278:H33-H40.
35. Cataliotti A, BuNnett JC Jr: Natriuretic peptides: novel therapeutic targets in heart failure. J Investig Med 2005, 53:378-384.
36. Yancy CW, Singh A: Potential applications of outpatient nesiritide in fusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial). Am J Cardiol 2006, 98:226-229.
37. Yancy CW, Krum H, Massie BM, et al.: Safety and efficacy of outpatient nesiritide in patients with chronic decompensated heart failure: Results of the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial. Circulation: Heart Failure (in press).
38. Burnett JC Jr, Korinek J: The tuPultuous journey of nesiritide: past, present and future. Circulation: Heart Failure (in press).
39. Chen HH, Schirger JA, Cataliotti A, Burnett JC Jr: Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Eur J Heart Fail 2006, 8:681-686.
40. Chen HH, Huntley BK, Schirger JA, et al.: Maximizing the renal cyclic 3′-5′-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: A novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol 2006, 17:2742-2747.
41. Chen HH, Redfield MM, Nordstrom LJ, et al.: Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 2004, 10:115-119.
42. Wang W, Ou Y, Shi Y: AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res 2004, 21:2105-2111.
43. Gill HS, Prausnitz MR: Coating formulations for microneedles. Pharm Res 2007, 24:1369-1380.
44. Prescott JH, Lipka S, Baldwin S, et al.: Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotechnol 2006, 24:437-438.
45. Stevens TL, Burnett JC Jr, Kinoshita M, et al.: A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 1995, 95:1101-1108.
46. Joseph R, Pahari S, Hodgson WC, Kini RM: Hypotensive agents from snake venoms. Curr Drug Targets Cardiovasc Haematol Disord 2004, 4:437-459.
47. Singh G, Kuc RE, Maguire JJ, et al.: Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: Downregulation of natriuretic peptide receptor-A in heart failure. Circ Res 2006, 99:183-190.
48. Margulies KB, Burnett JC Jr: Visualizing the basis for paracrine natriuretic peptide signaling in human heart. Circ Res 2006, 99:113-115.
49. Chen HH, Lainchbury JG, Burnett JC Jr: Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol 2002, 40:1186-1191.
50. Lainchbury JG, Lisy O, Burnett JC Jr, et al.: Actions of a novel synthetic natriuretic peptide on hemodynamics and ventricular function in the dog. Am J Physiol Regul Integr Comp Physiol 2002, 282:R993-R998.
51. Lisy O, Lainchbury JG, Leskinen H, Burnett JC Jr: Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension 2001, 37:1089-1094.
52. Wei CM, Kim CHA Miller VM, Burnett JC Jr: Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993, 92:2048-2052.
53. Lisy O, Huntley BK, McCormick DJ, et al.: Design, synthesis and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2003 (in press).
54. Martin FL, Stevens TL, Cataliotti A, et al.: Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int 2005, 67:1723-1730.
55. Rouleau JL, Pfeffer MA, Stewart DJ, et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000, 356:615-620.
56. Guazzi M, Samaja M, Arena R, et al.: Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007, 50:2136-2144.
57. Chen HH, Lainchbury JG, Harty GJ, Burnett JC Jr: Maximizing the natriuretic peptide system in experimental heart failure: Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 2002, 105:999-1003.
58. Boerrigter G, Costello-Boerrigter LC, Lapp H, et al.: Beneficial actions of co-targeting particulate and soluble guanylate cyclase dependent cGMP pools in experimental heart failure [abstract 2494]. Circulation 2007, 116:II-550.
59. Forfia PR, Lee M, Tunin RS, et al.: Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 2007, 49:1079-1088.
60. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al.: Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004, 109:1680-1685.